FDA Approves Daratumumab and Hyaluronidase-fihj in Combination for MM

On July 9, 2021, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma (MM) who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor.

Read the FDA announcement.

Read Janssen's announcement.

Posted 7/12/2021